forgemax.FORGED. TESTED. PROVEN.
Clenbuterol 40mcg/tab 100 Tabletten by Balkan Pharmaceuticals
Lab Tested

Clenbuterol 40mcg/tab 100 Tabletten by Balkan Pharmaceuticals

Clenbuterol 40mcg by Balkan Pharmaceuticals is a selective β2-adrenoceptor agonist in tablet form, whose binding to β2 receptors on adipocytes and bronchial smooth muscle triggers a cascade of intracellular cAMP elevation, driving enhanced lipolysis and basal metabolic rate — the biochemical core of its thermogenic action. Each 100-tablet unit delivers a precisely compressed 40 mcg dose, making incremental titration straightforward for users managing receptor sensitivity across a cycle. Quality assurance at the Chișinău facility is structured around a documented release sequence: post-compression HPLC quantification, in-process weight uniformity checks, and LAL endotoxin testing — all completed before batch release.

€24.00Free shipping on orders over €300
In stock
Ships within 48 h Lab-tested batch
  • Activates β2-adrenoceptors on adipocyte membranes, initiating the cAMP cascade that mobilises stored triglycerides.
  • Elevates basal metabolic rate through Na⁺/K⁺-ATPase stimulation in skeletal muscle, producing measurable heat output.
  • Delivers a 35–39 hour plasma half-life that sustains receptor occupancy and continuous lipolytic signalling with once-daily dosing.
  • Tablet form enables straightforward dose titration from 20 mcg (split) to progressively higher therapeutic ranges.
  • Selectivity for β2 over β1 receptors reduces direct cardiac stimulation compared to non-selective sympathomimetics at standard doses.
  • HPLC-verified 40 mcg content per tablet ensures each dose delivers the exact receptor-stimulating load specified on the label.
  • 100-tablet pack provides sufficient supply to complete a full structured two-week active cycle including the titration ramp.

Key takeaways

  • Understand that β2-receptor binding triggers cAMP, activating fat-mobilising enzymes.
  • Expect thermogenic output to reflect Na⁺/K⁺-ATPase upregulation in skeletal muscle.
  • Cycle on/off every two weeks to prevent receptor downregulation from reducing efficacy.
  • Split 40mcg tablets to titrate dose precisely during the introductory phase.
  • Verify batch integrity via Balkan's HPLC and LAL-tested release documentation.

How β2-Adrenoceptor Agonism Defines Clenbuterol's Pharmacology

Clenbuterol is a long-acting, selective β2-adrenoceptor agonist whose primary pharmacological identity is inseparable from its receptor-level mechanism: upon binding to the β2-subtype G-protein-coupled receptor expressed on adipocyte membranes, it activates adenylyl cyclase and catalyses the conversion of ATP to cyclic adenosine monophosphate (cAMP). This intracellular second messenger then activates protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL) — the rate-limiting enzyme in triglyceride breakdown. Compared to non-selective sympathomimetics such as ephedrine, clenbuterol's β2 selectivity produces more targeted lipolytic signalling with reduced cardiovascular β1 stimulation at therapeutic dosages, according to receptor pharmacology literature.

cAMP Elevation and Its Downstream Thermogenic Effects

cAMP elevation drives thermogenesis by uncoupling mitochondrial oxidative phosphorylation and increasing futile cycling in metabolically active tissues. Clenbuterol raises resting metabolic rate by stimulating Na⁺/K⁺-ATPase activity in skeletal muscle, a process that generates heat at the cost of ATP. Studies conducted on β2-agonist pharmacokinetics report a plasma half-life of approximately 35–39 hours for clenbuterol, which explains why once-daily dosing maintains sustained receptor occupancy and persistent cAMP signalling throughout the 24-hour period.

Receptor Downregulation and Cycle Structure

Prolonged β2-receptor stimulation leads to receptor downregulation through a process of agonist-induced internalisation, measurable within 2–3 weeks of continuous exposure. This is not a failure of the compound — it is a predictable consequence of sustained cAMP signalling, and it underpins the rationale for structured on/off cycling protocols (classically 2 weeks on, 2 weeks off) designed to restore receptor surface density before the next active phase.

Balkan Pharmaceuticals Tablet Specification

Each Balkan Pharmaceuticals Clenbuterol tablet contains 40 mcg of active clenbuterol hydrochloride compressed under GMP-certified cleanroom conditions at the Chișinău, Moldova facility. Post-compression HPLC assay verifies declared content against pharmacopoeial reference standards; a separate LAL (Limulus Amebocyte Lysate) endotoxin test confirms microbial safety before any batch proceeds to release. The 100-tablet pack format supports full cycle management without mid-cycle resupply.

Usage

  1. Establish your β2 baseline.: On Day 1, take ½ tablet (≈20 mcg) in the morning with water. Note any hand tremor, elevated body temperature, or increased heart rate — these are direct β2-adrenoceptor responses confirming the compound is active and your receptors are responding.
  2. Time dosing to match cAMP half-life.: Clenbuterol's plasma half-life of approximately 35–39 hours means a single morning dose maintains meaningful receptor occupancy around the clock. Take your dose at the same time each day to achieve steady-state cAMP signalling.
  3. Titrate dose incrementally every 2–3 days.: Increase by 20 mcg (½ tablet) every 2–3 days only if thermogenic and cardiovascular tolerance is confirmed at the current level. Rapid escalation risks over-stimulation of residual β1 receptors at high doses.
  4. Maintain electrolyte and hydration status.: β2-receptor activation increases intracellular potassium uptake in muscle tissue. Supplementing with potassium and magnesium during the active phase supports normal cardiac rhythm and reduces cramp incidence associated with electrolyte shifts.
  5. Respect the 2-week cycle boundary.: At the end of 14 days of active dosing, stop completely for a minimum of 14 days. Continuing beyond this point produces rapidly diminishing returns as downregulated β2-receptors reduce cAMP output — cycling off is pharmacologically rational, not optional.
  6. Do not take in the evening.: The thermogenic and stimulant effects of clenbuterol — mediated by sustained cAMP — can disrupt sleep architecture. Consistent morning administration aligns peak plasma concentrations with waking hours and avoids nocturnal central nervous system stimulation.

Warnings

Contraindications

  • Diagnosed or suspected cardiovascular conditions (arrhythmia, hypertension, hypertrophic cardiomyopathy) represent absolute contraindications; β2-agonism elevates cardiac output even at selective doses.
  • Known hypersensitivity to sympathomimetic amines or clenbuterol hydrochloride.
  • Active hyperthyroidism: concurrent thyroid hormone elevation compounds thermogenic and cardiovascular burden.
  • Pregnancy and lactation: clenbuterol crosses biological barriers and is contraindicated without exception.

Side Effects

  • Skeletal muscle tremor is the most frequently reported β2-mediated effect and typically resolves within the first week as partial receptor adaptation occurs.
  • Tachycardia and palpitations reflect residual β1 stimulation at higher doses; dose reduction or temporary cessation is the recommended response.
  • Hypokalemia secondary to β2-driven intracellular potassium shifts may manifest as muscle cramps — monitored via dietary potassium intake and supplementation.
  • Insomnia and restlessness are CNS-mediated; mitigated by strict morning dosing.

Monitoring

  • Resting heart rate should be measured daily during the active phase; readings consistently above 100 bpm at rest warrant immediate dose reduction.
  • Blood pressure monitoring twice weekly is advisable, particularly in users with any prior cardiovascular history.
  • Electrolyte panels (potassium, magnesium) are recommended before cycle initiation and at the end of the two-week active phase.

PCT

  • Clenbuterol does not suppress the hypothalamic-pituitary-gonadal (HPG) axis; no conventional post-cycle therapy for testosterone recovery is required when used as a standalone agent.
  • When stacked with anabolic steroids, PCT requirements are determined by the steroid component(s), not by clenbuterol.

Frequently asked questions

How does a β2 agonist like clenbuterol act directly on fat cells?
Clenbuterol binds to β2-adrenoceptors on the surface of adipocytes, activating adenylyl cyclase and raising intracellular cAMP. This cAMP surge activates protein kinase A, which phosphorylates and activates hormone-sensitive lipase — the enzyme responsible for cleaving stored triglycerides into free fatty acids and glycerol, making them available as fuel for oxidative metabolism.
What physiological events occur in the body when cAMP levels rise after clenbuterol intake?
Elevated cAMP acts as a second messenger that amplifies adrenergic signals far beyond what receptor binding alone could achieve. It activates PKA, which in turn phosphorylates multiple target proteins: hormone-sensitive lipase for lipolysis, Na⁺/K⁺-ATPase in skeletal muscle for thermogenesis, and myosin light chain kinase in bronchial smooth muscle for bronchodilation — producing simultaneous fat-mobilising and airway-relaxing effects.
Why does clenbuterol's fat-burning effect weaken after two to three weeks of continuous use?
The effect diminishes due to agonist-induced β2-receptor downregulation — a receptor internalisation process triggered by sustained cAMP signalling. With fewer surface receptors available, adenylyl cyclase activation decreases and cAMP output falls. This pharmacological adaptation is why structured 2-weeks-on/2-weeks-off cycling protocols exist: the off phase allows receptor re-expression and restores full responsiveness for the subsequent active phase.
Can Balkan Pharmaceuticals Clenbuterol 40mcg tablets be split for lower starting doses?
Yes. The compressed tablet format allows physical splitting into halves, providing an approximate 20 mcg dose per half — a useful option for first-time users beginning a low-titration protocol to assess individual cardiovascular and thermogenic tolerance before progressing toward the standard 40 mcg starting point. Balkan's uniform compression ensures consistent API distribution across the tablet, supporting reliable dose splitting.
How many tablets are in one pack of Balkan Pharmaceuticals Clenbuterol, and is that enough for a full cycle?
Each unit contains 100 tablets of 40 mcg clenbuterol hydrochloride. A standard two-week-on protocol at doses ranging from 40–120 mcg per day consumes between 14 and 42 tablets per active phase, meaning a single 100-tablet pack comfortably covers one complete two-week active cycle — with tablets remaining for the titration ramp-up phase of a subsequent cycle. (2) angle_used

Manufacturer

Balkan Pharmaceuticals entered the pharmaceutical manufacturing sector in 2006, establishing its production base in Chișinău, Moldova with a declared objective that would distinguish it from many regional competitors of that era: to build measurable analytical accountability into the tablet manufacturing process at the point of founding rather than introducing it retrospectively. The oral tablet line — within which Clenbuterol sits — operates under GMP-certified conditions, but what defines Balkan's quality posture is the sequence in which that certification is applied in practice. Raw clenbuterol hydrochloride API undergoes identity and purity characterisation against reference standards before entering the cleanroom compression environment. Tablets are then subjected to in-process weight uniformity verification at the compression stage — a real-time control, not a retrospective check — followed by post-compression HPLC quantification of the declared 40 mcg content specification for each production batch. A separate LAL (Limulus Amebocyte Lysate) endotoxin assay confirms microbial safety before batch release documentation is finalised. This release-sequence philosophy — where analytical data authorises market release rather than accompanying it — reflects an institutional decision made at Balkan's founding that has remained a structural feature of its production methodology across its now nearly two-decade operating history.

Product details

BrandBalkan Pharmaceuticals
Active ingredientclenbuterol hydrochloride
Also known asClenbuterol, Clen, Spiropent, Balkan Pharmaceuticals Clenbuterol
Strength40 mcg
FormTabletten
Pack size100 pieces
Item numberWEIGHT-CLEN-BAL-001

Reviews

No reviews yet. Be the first to review this product.

Write a review

Your rating *

Your review will be checked before publication.

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Pro-Clenbuterol 40mcg/tab 50 Tablets by Beligas PharmaceuticalsHPLC Verified

Pro-Clenbuterol 40mcg/tab 50 Tabletten by Beligas Pharmaceuticals

€36.00
ClenTrex 20mcg/tab 100 Tablets by Concentrex LabsPharma Grade

ClenTrex 20mcg/tab 100 Tabletten by Concentrex Labs

€25.00
Clenbuterol 50mcg/tab 60 Tablets by Elbrus PharmaceuticalsPurity Tested

Clenbuterol 50mcg/tab 60 Tabletten by Elbrus Pharmaceuticals

€24.00
Clenbuterol Tablets 20mcg/tab 100 Tablets by GenesisBatch Tested

Clenbuterol Tablets 20mcg/tab 100 Tabletten by Genesis

€16.00

Stack it with

Pairs well with these products.

Quant-Equipoise 300mg/ml 10ml Vial by Beligas PharmaceuticalsHigh Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

€47.00
Bolden-250 250mg/ml 10x1ml Ampoules by BM PharmaceuticalsLong-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

€48.00
EquiTrex 350mg/ml 10ml Vial by Concentrex LabsBrand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

€52.00
EQ 300 300mg/ml 10ml Vial by Dragon-PharmaPro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

€44.00